Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Febit group, a provider of advanced and flexible genomic analysis solutions, has signed a strategic investment and technology development agreement with In-Q-Tel, a not-for-profit investment firm that delivers technology solutions.
Subscribe to our email newsletter
This strategic collaboration will further the development of Febit’s Geniom technology to detect pathogens more quickly and with increased reliability.
The technology development agreement with In-Q-Tel is anticipated to improve the sensitive, flexible, and fully automated Geniom platform for the multiplexed detection and classification of known and unknown pathogens for the special needs of bio security.
The strategic investment is the result of an extensive evaluation process and thorough testing of Febit’s technology.
Cord Staehler, CEO of Febit, said: “Febit’s partnership with In-Q-Tel enables us to focus on the field of pathogen detection, and further enhance an application-oriented device with well-defined requirements, similar to what we have developed in the field of microRNA analysis with the geniom RT analyzer.”